NCT03144622 is a clinical trial in Pulmonary Cancer, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT03144622?

NCT03144622 is sponsored by National Taiwan University Hospital.

What condition does NCT03144622 study?

NCT03144622 studies Pulmonary Cancer, Breast Neoplasms, Abdominal Cancer.

Is NCT03144622 still recruiting?

NCT03144622 is currently status unknown. Last updated 30 October 2019.

Last reviewed 2019-10-30 · How we verify

NCT03144622

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-FSPG PET/CT Imaging in Patients With Cancers

Status unknown Last updated 30 October 2019

What this trial tests

trial in Pulmonary Cancer in 120 participants. Status unknown.

Timeline

6 September 2016

Primary endpoint
31 December 2019

31 December 2022

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	6 September 2016
Primary completion	31 December 2019
Estimated completion	31 December 2022
Sites	1 location across Taiwan

Conditions studied

Pulmonary Cancer — all drugs for Pulmonary Cancer →
Breast Neoplasms — all drugs for Breast Neoplasms →
Abdominal Cancer — all drugs for Abdominal Cancer →

Sponsor

National Taiwan University Hospital

Who can join

20 and older, any sex, with Pulmonary Cancer or Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare the diagnostic performance of 18F-FDG and 18F-FSPG PET/CT in lung, breast, and abdominal cancers before undergoing therapy. In addition, the role of 18F-FSPG PET/CT in evaluating therapy response and prognosis will also be evaluated.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Application of PET Tracers in Molecular Imaging for Breast Cancer.
Boers J, de Vries EFJ, Glaudemans AWJM, Hospers GAP, et al · · 2020 · cited 25× · PMID 32627087 · DOI 10.1007/s11912-020-00940-9
Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers.
Cao PHA, Dominic A, Lujan FE, Senthilkumar S, et al · · 2024 · cited 20× · PMID 38627553 · DOI 10.1038/s41585-024-00869-9

Verify or expand the search:

Other recruiting trials for Pulmonary Cancer

Currently open trials in the same condition.

NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
NCT06934499 — Tunisian Lung Cancer Study · recruiting
NCT05857995 — Precision Lung Cancer Survivorship Care Intervention · NA · recruiting
NCT05977803 — Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin · NA · recruiting
NCT05521789 — Erector Spinae Block for Thoracic Surgery · Phase 4 · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03144622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 30 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03144622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing